Globus Medical Inc
Why Globus Medical Stock Rose 10% on January 9
On January 9, Globus Medical was trading at a stock price of $43.79, which is an ~9.91% rise from its closing price of $39.84 on January 8.
What to Expect from Varian’s Bottom Line in Q4 2018
Varian Medical Systems (VAR) is expected to report net income of $105.05 million in the fourth quarter of fiscal 2018.
What Does Stryker’s Valuation Trend Indicate?
Stryker’s (SYK) share price has been on an uptrend for the past 52 weeks.
Globus Medical: What Contributed to Its Valuations?
Globus Medical’s (GMED) revenue and EPS have grown at a five-year CAGR of 10.5% and 8.6%, respectively.
A Deep Look at Globus Medical’s Financial Performance
In 3Q17, Globus Medical (GMED) generated sales of $151.7 million compared to $135.6 million in 3Q16.
A Look at Globus Medical’s Segmental Performance
Sales of Globus Medical’s innovative fusion products rose to $80.2 million in 3Q17 compared to $68.4 million in 3Q16.
Taking Stock of Globus Medical’s Recent Acquisitions
Most of Globus Medical’s revenue comes from the United States, and the rest comes from its international segment. In 3Q17, the United States contributed $125.9 million.
Analyst Ratings for Globus Medical and Its Peers in February
Of the 13 analysts covering Globus Medical in February 2018, seven of them have given the stock a “buy” or higher rating. Five analysts have given it a “hold.”
Behind MiMedx Group’s Recent Financial Performance
In 3Q17, MiMedx Group’s (MDXG) net sales rose to $84.6 million, compared with $64.4 million in 3Q16—a 31% YoY (year-over-year) rise.
Why the Physician Office Pain Management Market Matters to MiMedx
Through MiMedx’s donor program, a mother scheduled to deliver a baby by C-section can donate her placental tissue rather than leave it as medical waste.
Which Markets Is MiMedx Group Actually Targeting?
MiMedx estimates that the domestic skin and dermal substitute market will reach sales of $1.1 billion in 2020.
Understanding MiMedx Group’s Zealous Focus on Sales
MiMedx focuses on marketing efforts to increase revenues. The company has at its disposal a sales force of 320 professionals.
MiMedx Group on the Street: Analyst Recommendations in January
Of the four analysts covering MiMedx Group in January 2018, three have given the stock a “buy” rating, and one analyst has given it a “strong buy” rating.
How Have IHI’s Mid-Capitalization Stocks Performed?
On June 9, 2016, the top performer within the mid-capitalization space of the iShares U.S. Medical Devices ETF was Idexx Laboratories, which rose by 1.5%.
Which Stocks in IHI Are Trading above Their Moving Averages?
The iShares US Medical Devices ETF (IHI) went down by 0.55% to close at $123.18 on December 2.